Orion Oyj (ORINF) Stock Price, News & Analysis

Company Overview

Orion Oyj is a Finland-based pharmaceutical and diagnostic products company that develops, manufactures and markets both human and veterinary medicines, diagnostic tests and active pharmaceutical ingredients. With a history dating back to its founding in 1917, the company has evolved into a diversified life science group, offering prescription and over-the-counter products for neurological, respiratory, cardiovascular and urological conditions, among others. Orion’s human pharmaceuticals portfolio includes well-known treatments for Parkinson’s disease, hormone therapy and erectile dysfunction, while its veterinary range addresses animal health needs such as pain management and dermatology.

In its Diagnostics segment, Orion produces laboratory tests and instruments for clinical chemistry and immunoassay applications, focusing on hormone and drug monitoring. These diagnostic products support healthcare providers and research institutions in more than 90 countries, facilitating patient care and scientific study. The company’s Active Pharmaceutical Ingredients (API) unit supplies customized chemical compounds and intermediates to third-party drug manufacturers, leveraging advanced chemistry capabilities built over decades of pharmaceutical expertise.

Headquartered in Espoo, Finland, Orion combines research and development activities with manufacturing operations in Europe and Asia. The company invests significantly in its R&D centers to discover and advance new molecular entities and formulations, partnering with academic institutions and biotech firms to expand its drug pipeline. Orion also maintains quality-focused production sites, ensuring compliance with international regulatory standards and supporting global distribution networks.

Orion’s governance structure features an executive leadership team headed by a President and CEO and overseen by a Board of Directors. The company’s long-term strategy emphasizes innovative drug discovery, expansion of specialty pharmaceuticals and growth in diagnostics markets. Through sustainable practices and stakeholder engagement, Orion strives to address unmet medical needs, enhance patient outcomes and deliver value to healthcare systems worldwide.

Key Stats

• Today's Range: $81.30 to $81.30
• 50-Day Range: $47.79 to $81.30
• 52-Week Range: $48.65 to $81.30
• Volume: N/A
• Average Volume: 1,080 shs
• Market Capitalization: N/A
• P/E Ratio: 50.60
• Dividend Yield: 1.54%
• Price Target: N/A
• Consensus Rating: N/A

ORINF Stock Analysis - Frequently Asked Questions

How have ORINF shares performed this year?

Orion Oyj's stock was trading at $48.65 at the beginning of 2025. Since then, ORINF shares have increased by 67.1% and is now trading at $81.30.

How do I buy shares of Orion Oyj?

Shares of ORINF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 9/17/2025
• Next Earnings (Estimated): 10/28/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Drug Manufacturers - General
• Sub-Industry: Personal Services
• Current Symbol: OTCMKTS:ORINF
• CIK: N/A
• Web: www.orion.fi
• Phone: 358104261
• Fax: N/A
• Employees: 3,819
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: 50.60
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A